- Home
- VALU vs IGMS Comparison
VALU vs IGMS Comparison
Compare VALU & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALU
- IGMS
- Stock Information
- Founded
- VALU 1931
- IGMS 1993
- Country
- VALU United States
- IGMS United States
- Employees
- VALU N/A
- IGMS N/A
- Industry
- VALU Investment Managers
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- VALU Finance
- IGMS Health Care
- Exchange
- VALU Nasdaq
- IGMS Nasdaq
- Market Cap
- VALU 491.0M
- IGMS 528.6M
- IPO Year
- VALU N/A
- IGMS 2019
- Fundamental
- Price
- VALU $53.01
- IGMS $7.48
- Analyst Decision
- VALU
- IGMS Buy
- Analyst Count
- VALU 0
- IGMS 8
- Target Price
- VALU N/A
- IGMS $16.25
- AVG Volume (30 Days)
- VALU 10.3K
- IGMS 213.0K
- Earning Date
- VALU 12-13-2024
- IGMS 11-08-2024
- Dividend Yield
- VALU 2.22%
- IGMS N/A
- EPS Growth
- VALU 26.35
- IGMS N/A
- EPS
- VALU 2.36
- IGMS N/A
- Revenue
- VALU $35,859,000.00
- IGMS $2,918,000.00
- Revenue This Year
- VALU N/A
- IGMS $386.95
- Revenue Next Year
- VALU N/A
- IGMS N/A
- P/E Ratio
- VALU $22.72
- IGMS N/A
- Revenue Growth
- VALU N/A
- IGMS 57.64
- 52 Week Low
- VALU $36.00
- IGMS $6.17
- 52 Week High
- VALU $57.68
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- VALU 58.30
- IGMS 31.53
- Support Level
- VALU $51.74
- IGMS $7.00
- Resistance Level
- VALU $53.29
- IGMS $10.80
- Average True Range (ATR)
- VALU 1.29
- IGMS 0.96
- MACD
- VALU 0.11
- IGMS -0.10
- Stochastic Oscillator
- VALU 93.32
- IGMS 8.33
About VALU Value Line Inc.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.